^
    7ms
    Safety and Tolerability of SYNB1891 Injection Alone or in Combination With Atezolizumab in Adult Participants (clinicaltrials.gov)
    P1, N=32, Terminated, Synlogic | N=70 --> 32 | Recruiting --> Terminated; Business reasons
    Enrollment change • Trial termination • Combination therapy • Metastases
    |
    Tecentriq (atezolizumab) • SYNB1891
    over3years
    [VIRTUAL] Intratumoral injection of SYNB1891, a synthetic biotic designed to activate the innate immune system, demonstrates target engagement in humans including intratumoral STING activation (AACR 2021)
    Repeat IT injection of SYNB1891 as monotherapy is safe and well-tolerated up to at least 3x107 cells and shows evidence of STING pathway target engagement. These data support the continued dose escalation of SYNB1891 as monotherapy, and initiation of Arm 2 in combination with atezolizumab.
    PD(L)-1 Biomarker • IO biomarker
    |
    IFNG (Interferon, gamma) • IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • CXCL10 (Chemokine (C-X-C motif) ligand 10) • PD-L2 (Programmed Cell Death 1 Ligand 2) • CXCL9 (Chemokine (C-X-C motif) ligand 9) • CD4 (CD4 Molecule) • STING (stimulator of interferon response cGAMP interactor 1) • GZMA (Granzyme A) • IFIT1 (Interferon Induced Protein With Tetratricopeptide Repeats 1) • IL1R1 (Interleukin 1 receptor, type I) • TNFSF10 (TNF Superfamily Member 10)
    |
    Tecentriq (atezolizumab) • SYNB1891